JACOBIO's subsidiary transfers 80% equity of JACOBIO-Kang, involving 200 million RMB
JACOBIO-B (01167.HK) announced that its controlling subsidiary Beijing JACOBIO is transferring 80% equity of JACOBIO to Haisong Capital, with a total consideration of 200 million RMB, including a cash down payment of 125 million RMB and a second milestone payment of 75 million RMB. The proceeds are intended to be used for the research and development, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects.
Upon completion, Beijing JACOBIO's shareholding in JACOBIO will be reduced to 10%, the latter being a project company for the group's early cardiovascular research and development project
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments